DeutschFrom bench to bedside – A mission for a healthy life
From bench to bedside – A mission for a healthy life
The DRFZ investigates the long‐term outcomes of rheumatic diseases, including the impact of current treatment options, in order to inform clinical decision making, identify unmet needs and improve health care. Biomedical research identifies the cells initiating and those driving rheumatic diseases, and the underlying molecular mechanisms. Our aim is the development of improved, personalised, at best curative therapies for patients with rheumatic diseases, and their rapid translation into clinical practice.
News
Rheumatological care of pregnant axial spondyloarthritis patients is important
Is IgM Fc receptor (FcμR) expressed by innate immune cells?
Using mathematical modeling to unravel critical components in the survival of bone marrow memory plasma cells
Mechanical forces link bone matrix mineralization and inhibition of angiogenesis to limit adolescent bone growth
Science at DRFZ
Peter Jani: tbs
Moritz Pfeifenberger: Development of a cartridge-based bioreactor platform for parallelized cultivation and stimulation of complex tissue models
Murat Torgutalp: The effect of treatment on radiographic spinal progression in patients with axial spondyloarthritis: long-term result from German Spondyloarthritis Inception Cohort
Mario Witkowski: Postnatal ILC homeostasis and function is controlled by microRNA regulomes
Mediathek
News | 11. April 2022
Prof. Elisabeth Märker-Hermann
... is the new President of the Board of Trustees
News | 10. March 2022
Anja Strangfeld
... is the new head of the Programme Area Epidemiology at the DRFZ
News | 05. January 2022
Uta Bielfeldt
... is the new Administrative Director of the German Rheumatism Research Centre Berlin (DRFZ), a Leibniz Institute, since 1 January 2022.